Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor [0.03%]
利用肿瘤引流淋巴结的力量：揭示免疫检查点抑制剂的预测生物标志物
Zihan Chen,Jiangnan Yu,Zhikun Guo et al.
Zihan Chen et al.
With the escalating application of immune checkpoint inhibitors (ICIs) in solid tumors, these therapies have demonstrated clinical benefits but remain hampered by relatively low response rates. Reliable biomarkers to predict ICIs responsive...
Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control [0.03%]
基于细胞因子的胃癌免疫治疗：靶向炎症控制肿瘤生长
Mathan Muthu Chinakannu Marimuthu,Bhavani Sowndharya Balamurugan,Vickram Agaram Sundaram et al.
Mathan Muthu Chinakannu Marimuthu et al.
Emerging cancer immunotherapy methods, notably cytokine-based ones that modify immune systems' inflammatory reactions to tumor cells, may help slow gastric cancer progression. Cytokines, tiny signaling proteins that communicate between immu...
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation [0.03%]
基于新抗原的免疫治疗：通过发现和创新推进癌症和胶质母细胞瘤的精准医疗
Moawiah M Naffaa,Ola A Al-Ewaidat,Sopiko Gogia et al.
Moawiah M Naffaa et al.
Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique t...
Viral infections and immune modulation in bladder cancer: implications for immunotherapy [0.03%]
病毒感染和免疫调控在膀胱癌中的作用：对免疫治疗的启示
Lívia Bitencourt Pascoal,Mehrsa Jalalizadeh,Gabriela Barbosa et al.
Lívia Bitencourt Pascoal et al.
This review explores the intricate relationship between viral infections and Bacillus Calmette-Guerin (BCG) efficacy, emphasizing immune modulation mechanisms that may influence treatment outcomes. Since its introduction in 1976, intravesic...
Jack G Fisher,Laura G Bartlett,Trinayan Kashyap et al.
Jack G Fisher et al.
Exportin-1 (XPO1) is a nuclear export protein that, when overexpressed, can facilitate cancer cell proliferation and survival and is frequently overexpressed or mutated in cancer patients. As such, selective inhibitors of XPO1 (XPO1i) funct...
Eosinophil cytolysis with or without ETosis in four cases of human gastric cancer: a comparative ultrastructural study [0.03%]
四例人类胃癌中嗜酸性粒细胞的ETosis参与下的和非参与下的细胞溶解：一项比较性超微结构研究
Rosario Caruso,Valerio Caruso,Luciana Rigoli
Rosario Caruso
The ultrastructural morphology of eosinophil cytolysis and extracellular trap cell death (ETosis) has predominantly been examined in non-neoplastic eosinophil-associated diseases, with a limited investigation in neoplasms. This current elec...
Suphiya Parveen,Dhanshree Vikrant Konde,Safal Kumar Paikray et al.
Suphiya Parveen et al.
Immunotherapy has gathered significant attention and is now a widely used cancer treatment that uses the body's immune system to fight cancer. Despite initial successes, its broader clinical application is hindered by limitations such as he...
Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances [0.03%]
利用现有知识克服恩沃单抗和帕博利珠单抗治疗尿路上皮癌患者耐药性的策略：为未来的研究奠定基础
Albert Jang,Jason R Brown
Albert Jang
The combination of enfortumab vedotin and pembrolizumab (EVP) has been recently approved for patients with locally advanced and metastatic urothelial carcinoma. This combination showed a higher objective response rate and superior progressi...
Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma [0.03%]
仑伐替尼联合派姆单抗治疗中高危转移性肾细胞癌的预后效果研究
Ilya Tsimafeyeu,Alexander Sultanbaev,Daria Dubovichenko et al.
Ilya Tsimafeyeu et al.
The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the tr...
Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies [0.03%]
肿瘤微环境中的关键免疫细胞及其相互作用：膀胱癌创新疗法的启示
Anna Di Spirito,Sahar Balkhi,Veronica Vivona et al.
Anna Di Spirito et al.
Bladder cancer (BC) is a heterogeneous disease associated with high mortality if not diagnosed early. BC is classified into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC), with MIBC linked to poor systemic therapy response and...